TMEM165 Recombinant antibody

TMEM165 Recombinant Antibody for IF, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

Human

Applications

IF, ELISA

Conjugate

Unconjugated

CloneNo.

230517B1

Cat no : 83146-1-RR

Synonyms

TMEM165, TMPT27, TPARL, transmembrane protein 165, Transmembrane protein PT27, Transmembrane protein TPARL

---

Validation Data Gallery

• 

  IF Staining of HepG2 using 83146-1-RR

  Immunofluorescent analysis of (4% PFA) fixed HepG2 cells using TMEM165 antibody (83146-1-RR, Clone: 230517B1 ) at dilution of 1:400 and CoraLite®488-Conjugated AffiniPure Goat Anti-Mouse IgG(H+L) (SA00013-1), CL594-Phalloidin (red).

---

Tested Applications

• Positive IF detected in: HepG2 cells

Recommended dilution

• Immunofluorescence (IF): IF : 1:200-1:800

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Product Information

83146-1-RR targets TMEM165 in IF, ELISA applications and shows reactivity with Human samples.

• Tested Reactivity: Human
• Host / Isotype: Rabbit / IgG
• Class: Recombinant
• Type: Antibody
• Immunogen: TMEM165 fusion protein Ag14362
• Full Name: transmembrane protein 165
• Calculated Molecular Weight: 324 aa, 35 kDa
• GenBank Accession Number: BC003545
• Gene Symbol: TMEM165
• Gene ID (NCBI): 55858
• Conjugate: Unconjugated
• Form: Liquid
• Purification Method: Protein A purification
• Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
• Storage Conditions: Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage. 20ul sizes contain 0.1% BSA.

Background Information

Thiopurine methyltransferase or thiopurine S-methyltransferase (TPMT), a member of methyltransferase superfamily, is an enzyme involved in the normal metabolic inactivation of thiopurine drugs such as azathioprine, 6-mercaptopurine and 6-thioguanine. These drugs are generally used as immunosupressants or cytotoxic drugs and are prescribed for a variety of clinical conditions including leukemia, autoimmune disease and organ transplantation. Defects in the TPMT gene leads to decreased methylation and decreased inactivation of 6MP leading to enhanced bone marrow toxicity which may cause myelosuppression, anemia, bleeding tendency, leukopenia and infection.